Next Article in Journal
Differential Effects of Ischemia and Inflammation on Plasma-Derived Extracellular Vesicle Characteristics and Function in a Mouse Model
Next Article in Special Issue
From Mechanisms to Therapeutic Innovation in Non-Small Cell Lung Cancer: A Knowledge-Depth Translational Mapping with Experimental Validation
Previous Article in Journal
Adipose-Tissue Macrophage Diversity and Functions
Previous Article in Special Issue
Common Biomarkers in Chronic Obstructive Pulmonary Disease and Bronchopulmonary Dysplasia: A Narrative Review of an Intriguing Interplay
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 4
10.3390/ijms27041761
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension

by
Maria E. de S. F. Onofre
1,
Renata T. Santos
1,
Nazareth de N. Rocha
1,2,
Dayene de A. F. Caldeira
1,
Johnatas D. Silva
1,*,
Carla M. da Silva
1,
Monique M. Melo
1,
Mayck M. A. da Silva
1,
Clara R. S. Pastor
1,
Julia D. Batista
1,
Isadora A. Botelho
1,
Rodrigo G. Veras
1,
Sabrina S. de S. Serra
1,
Julianna D. Zeidler
1,
Patricia R. M. Rocco
1,
Fernanda F. Cruz
1 and
Pedro L. Silva
1,*
1
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
2
Instituto Biomedico, Universidade Federal Fluminense, Niterói 24120-130, RJ, Brazil
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(4), 1761; https://doi.org/10.3390/ijms27041761
Submission received: 16 January 2026 / Revised: 10 February 2026 / Accepted: 10 February 2026 / Published: 12 February 2026
(This article belongs to the Special Issue Advances in Lung Research: From Mechanisms to Therapeutic Innovation)
Browse Figures
Review Reports Versions Notes

Abstract

Pulmonary arterial hypertension (PAH) is characterized by progressive vascular remodeling and right ventricular (RV) dysfunction, processes that are increasingly associated with disturbances in cellular metabolism. We investigated whether transplantation of exogenous mitochondria derived from bone marrow mesenchymal stromal cells, alone or combined with sildenafil, could improve mitochondrial homeostasis and attenuate cardiopulmonary remodeling in monocrotaline-induced PAH. Male Wistar rats were assigned to control (CTRL, n = 8) or PAH (n = 32) groups. Fourteen days after induction of PAH, animals were randomized to receive saline, sildenafil (20 mg/kg/day for 14 days), intravenous mitochondrial transplantation (100 μg, days 14 and 21), or combined therapy. On day 28, echocardiography, invasive measurement of RV systolic pressure (RVSP), pulmonary vascular histology, gene expression analyses (vimentin, VE-cadherin, and mitochondrial metabolism–related genes), and high-resolution respirometry were performed. All treatments significantly reduced RVSP compared with untreated PAH. Mitochondrial therapy, alone or combined with sildenafil, decreased arteriolar α-smooth muscle actin content, whereas endothelial–mesenchymal transition was attenuated only with combined treatment. Mitochondrial transplantation and sildenafil increased Complex I–dependent respiration, whereas Complex IV activity improved exclusively with mitochondrial therapy. Combined treatment reduced plasma IL-6 and IL-1β levels compared with PAH. Thus, mitochondrial transplantation, particularly when combined with sildenafil, improved RV function, limited pulmonary vascular remodeling, reduced plasma inflammatory markers, and changed key mitochondrial pathways in experimental PAH.

1. Introduction

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease characterized by structural remodeling of the pulmonary vasculature, leading to luminal narrowing, impaired pulmonary blood flow, and increased pulmonary vascular resistance [1]. Despite major advances in pharmacological therapy, the prognosis of patients with group 1 PAH, including idiopathic, heritable, drug-induced, and associated forms such as connective tissue disease and congenital heart disease, remains poor; median survival is approximately 6 years [2]. Currently approved therapies predominantly target vasoregulatory pathways and provide symptomatic and hemodynamic improvement, but they do not reliably prevent, halt, or reverse the structural vascular remodeling that drives disease progression [3,4,5,6,7].
Increasing evidence indicates that PAH is also a disorder of cellular metabolism, characterized by mitochondrial dysfunction and metabolic reprogramming within the pulmonary vasculature and the right ventricle [8]. Impaired oxidative phosphorylation, altered mitochondrial dynamics, increased oxidative stress, and changes in mitochondrial content and quality control have been described in both experimental models and human PAH [9]. These abnormalities contribute to a hyperproliferative, apoptosis-resistant vascular cell phenotype and are increasingly recognized as integral components of the remodeling process.
In this context, mitochondrial transplantation (mitotherapy) has emerged as an experimental strategy to improve cellular bioenergetics. After the discovery of spontaneous intercellular mitochondrial transfer [10], exogenous mitochondrial delivery has been shown to influence tissue homeostasis in models of neurodegenerative, ocular, and ischemic cardiac diseases [11,12,13]. However, whether mitochondrial transplantation can meaningfully affect pulmonary vascular remodeling and cardiopulmonary physiology in PAH, beyond isolated cellular energetic effects, remains insufficiently characterized.
Mitochondria-targeted interventions have been proposed as a means to influence both pulmonary vascular remodeling and RV dysfunction. Although experimental studies suggest that mitochondrial transfer may stabilize mitochondrial membrane potential, reduce reactive oxygen species production, and restore mitochondrial dynamics, several key questions remain unresolved. In particular, the effects of mitotherapy on pulmonary vascular structure, invasive hemodynamics, and mitochondrial metabolic pathways have not been systematically examined in established models of PAH [14,15]. Moreover, the importance of the source of mitochondria represents a critical and largely unexplored variable, given the marked tissue-specific differences in mitochondrial phenotypes and function.
Another unresolved issue is whether metabolic interventions, such as mitotherapy, might complement rather than replace established vasodilator therapies. Sildenafil, a phosphodiesterase-5 inhibitor, remains a cornerstone of PAH treatment through its effects on pulmonary vascular tone, but its impact on structural remodeling is limited. Whether targeting mitochondrial homeostasis can enhance or extend the biological effects of conventional hemodynamic therapy has not been tested.
Based on preliminary observations comparing mitochondria from different tissue sources, we hypothesized that mitochondria derived from bone marrow mesenchymal stromal cells (BM-MSCs), alone or in combination with sildenafil, could favorably improve mitochondrial homeostasis and attenuate pulmonary vascular remodeling in experimental PAH. We therefore designed this study to evaluate the effects of BM-MSC–derived mitochondrial transplantation, with or without sildenafil, on pulmonary hemodynamics, vascular remodeling, plasma levels of inflammatory markers, and mitochondrial metabolic pathways in a monocrotaline rat model of PAH.

2. Results

2.1. Biodistribution and Functional Characterization of Isolated Mitochondria

Fluorescence imaging demonstrated that intravenously administered mitochondria derived either from liver or BM-MSCs accumulated predominantly in the liver and kidneys at both 3 and 24 h after injection. In contrast, only minimal fluorescence signals were detected in the lungs and heart (Figure 1 and Figure S1), indicating limited pulmonary and cardiac biodistribution.
The median level of protein concentration in BM-MSC-derived mitochondria lysates was 52 mg/mL. BM-MSC-derived mitochondria had 86.3% ± 6.3% of particles positive for MitoTracker Deep Red FM. The functional properties of isolated mitochondria were assessed by high-resolution respirometry (Figure S2). Liver-derived mitochondria exhibited higher basal oxygen consumption and greater substrate-stimulated respiration than BM-MSC–derived mitochondria. After the addition of adenosine diphosphate (ADP), oxygen consumption increased markedly in liver-derived mitochondria (65.4 ± 4.8 pmol/s/mg), whereas only a modest increase was observed in BM-MSC–derived mitochondria (18.9 ± 2.8 pmol/s/mg), indicating preserved but limited phosphorylation capacity. Consistently, oligomycin-sensitive respiration revealed a substantially higher proton leak in liver-derived mitochondria (22.0 ± 3.0 pmol/s/mg) than in BM-MSC–derived mitochondria (4.9 ± 1.6 pmol/s/mg). Maximal uncoupled respiration induced by FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) was also markedly higher in liver-derived mitochondria (58.3 ± 9.7 pmol/s/mg) than in BM-MSC–derived mitochondria (22.6 ± 2.6 pmol/s/mg), indicating a greater respiratory reserve capacity. Despite their overall lower respiratory rates, BM-MSC–derived mitochondria retained measurable coupling efficiency.

2.1.1. Liver-Derived Mitochondria Induce Mortality in PAH Animals

All PAH animals receiving liver-derived mitochondria on day 14 died within a few days after injection (between days 20 and 26). In view of this unexpected and consistent lethality, subsequent experiments were performed exclusively using BM-MSC–derived mitochondria.

2.1.2. Effects on Right Ventricular Function and Hemodynamics

At day 14, PAH animals exhibited a reduced pulmonary artery acceleration time (PAT) to ejection time (PET) ratio and an increased right ventricular (RV) outflow tract diameter compared with control animals (Figure S3). At day 28, the PAT/PET ratio remained significantly reduced in all PAH groups, regardless of treatment (Figure 2A,B). RV outflow tract diameter remained increased in untreated PAH animals but was significantly reduced in animals treated with sildenafil alone or in combination with mitochondrial therapy (Figure 2A,C).
Right ventricular systolic pressure (RVSP) was markedly increased in PAH animals (50 ± 9 mmHg) compared with controls (20 ± 4 mmHg; p < 0.0001). All therapeutic interventions significantly reduced RVSP relative to untreated PAH animals (Figure 3). In contrast, the RV hypertrophy index was increased in PAH animals compared with controls and was not significantly modified by any treatment strategy (Figure 4).

2.1.3. Pulmonary Vascular Remodeling

Perivascular collagen deposition was significantly increased in PAH animals compared with controls. Treatment with sildenafil, BM-MSC–derived mitochondria, or their combination reduced collagen accumulation to a similar extent (Figure 5).
Pulmonary arterial muscularization, assessed by α-smooth muscle actin (α-SMA) expression, was markedly increased in PAH animals relative to controls. α-SMA expression was significantly reduced in animals treated with mitochondria alone or in combination with sildenafil, but remained unchanged in animals treated with sildenafil alone (Figure 6).

2.1.4. Markers of Endothelial-to-Mesenchymal Transition

Endothelial-to-mesenchymal transition (EndMT) was suggested by increased vimentin and reduced VE-cadherin mRNA expression in PAH animals compared with controls (Figure 7A,B). Vimentin expression was reduced in animals treated with sildenafil alone or in combination with mitochondria, but not in those treated with mitochondria alone. VE-cadherin expression was significantly increased only in the group receiving combined therapy, indicating a partial and treatment-specific attenuation of EndMT.

2.1.5. Mitochondrial Dynamics–Related Markers

Expression of succinate dehydrogenase complex, subunit A (Sdha) did not differ between PAH and control animals but was significantly reduced in animals treated with mitochondria alone or in combination with sildenafil (Figure 8A). Similarly, expression of mitochondrial transcription factor A (TFAM) was comparable between PAH and control animals but was decreased in all treated groups (Figure 8B).
Proteins involved in mitochondrial fusion displayed distinct patterns. Optic atrophy protein 1 (OPA1) expression was increased in PAH animals and was significantly reduced by all treatment strategies (Figure 8C). In contrast, mitofusin-1 (Mfn-1) expression did not differ between PAH and control animals but was consistently reduced across all treatment groups (Figure 8D).

2.2. Mitochondrial Respiratory Chain Activity

Mitochondrial oxygen flux through Complex I (CI + CIII + CIV) was similar in lung mitochondria from PAH and CTRL animals. However, Complex I–dependent respiration was significantly increased in mitochondria from animals treated with either sildenafil or mitochondrial therapy alone, whereas no significant change was observed in the combination therapy group (Figure S4A). No differences were detected in Complex II–dependent respiration among the groups (Figure S4B). Complex IV activity was significantly increased only in lung mitochondria from animals treated with mitochondria compared with controls (Figure S4C).

2.3. Plasma Levels of Inflammatory Markers

IL-6 and IL-1β plasma levels were higher in the PAH group than the CTRL group (p = 0.013 and p = 0.045, respectively) (Figure 9A,B). The combined therapy (PAH—sil & imt) decreased IL-6 and IL-1β plasma levels compared with the PAH group (p = 0.007 and p < 0.001, respectively). In addition, sildenafil combined with mitochondria transplantation showed lower IL-6 plasma level compared with PAH treated with sildenafil alone (p = 0.039) (Figure 9A). Figure S5A–C depicts a summary of the percentage changes of each therapy (Mitochondria alone, sildenafil alone, and combined therapy) compared with PAH.

3. Discussion

This study demonstrates that mitochondrial transplantation from BM-MSCs, either alone or in combination with sildenafil, attenuates several central features of experimental PAH. In monocrotaline-exposed rats, BM-MSC–derived mitochondrial administration reduced RVSP, perivascular collagen deposition, pulmonary arterial α-SMA expression, and the expression of genes related to mitochondrial homeostasis (Sdha, TFAM, OPA1, and Mfn-1), and selectively increased Complex IV activity in lung tissue. Sildenafil alone improved RV outflow tract diameter, reduced perivascular collagen accumulation, decreased vimentin and OPA1 expression, and increased Complex I activity. The combined treatment was associated with a broader pattern of biological effects, including reductions in RV outflow tract diameter, RVSP, perivascular collagen deposition, α-SMA, vimentin, Sdha, TFAM, OPA1, and Mfn-1, IL-6 and IL-1β plasma levels, together with restoration of VE-cadherin expression. These findings support the concept that metabolic modulation by mitochondrial transplantation complements established vasodilator therapy through partially overlapping and additive biological effects, rather than through true pharmacological synergy (Figure S5A–D).
The monocrotaline model was selected because of its reproducibility, cost-effectiveness, and ability to reproduce key features of human PAH, including endothelial dysfunction, pulmonary vascular inflammation, and progressive RV overload [16,17]. Although this model does not recapitulate complex plexiform lesions and is associated with systemic toxicity, it remains widely used to investigate mechanisms of pulmonary vascular remodeling and RV dysfunction [18]. PAT/PET and RV outflow tract diameter data from PAH animals at day 14 showed early signs of RV dysfunction. Translating to clinical practice, this would represent early echocardiographic manifestations of PAH, corresponding to a disease stage at which patients typically first seek medical evaluation. Sildenafil was chosen as a reference therapy because of its established clinical use as a phosphodiesterase-5 inhibitor that improves pulmonary hemodynamics through cGMP-mediated vasodilation [3]. The rationale for combining sildenafil with mitochondrial transplantation was to test whether targeting mitochondrial and metabolic abnormalities could enhance the effects of conventional hemodynamic therapy [12,13,14,15] (Figure S5A).
BM-MSC–derived mitochondria were selected based on their relative resistance to oxidative stress and their recognized immunomodulatory properties [19]. Although these mitochondria display lower maximal respiratory capacity than liver-derived mitochondria, they retain preserved coupling efficiency, a profile that may be advantageous in inflamed and oxidatively stressed microenvironments [20]. In a recent study from our group [21], mitochondria transplantation was evaluated in in vitro and in vivo models of acute lung injury induced by LPS. A trend toward reduction of ROS production (p = 0.072) was found after BM-MSC-derived mitochondria transplantation. In addition, BM-MSC-derived mitochondria transplantation reduced BALF neutrophils and total protein, denoting lung damage mitigation. Furthermore, previous studies have shown that stem cells are able to maintain their mitochondria structure, potentially through ATP hydrolyzation by ATP synthase, leading to high mitochondrial membrane potential [22,23,24]. A key and unexpected finding of the present study was that transplantation of liver-derived mitochondria was associated with death in PAH animals, despite their higher respiratory activity. This observation indicates that the biological effects of mitochondrial transplantation are not determined solely by bioenergetic performance. Mitochondria also function as signaling organelles involved in redox signaling, apoptosis regulation, calcium handling, and immune activation. Therefore, it is plausible that mitochondria with high metabolic activity may be poorly tolerated in the context of advanced pulmonary vascular disease, potentially due to metabolic mismatch, excessive redox signaling, or immune activation. Although the precise mechanism remains to be defined, this finding underscores the importance of the source and mitochondrial phenotype for both safety and efficacy [25,26].
Mitochondrial transplantation has emerged as a potential therapeutic strategy in diseases characterized by mitochondrial dysfunction [25,26,27,28]. This approach, initially explored in models of neurodegeneration, myocardial ischemia, and ocular disease, relies on the capacity of exogenous, respiration-competent mitochondria to be internalized by host cells and to influence cellular homeostasis through mechanisms that extend beyond the provision of ATP [13,24]. In PAH, where mitochondrial dysfunction contributes to abnormal vascular cell proliferation and apoptosis resistance, previous studies have suggested that mitochondrial transfer can attenuate vascular remodeling and improve right ventricular function. The present study extends these observations by demonstrating that BM-MSC–derived mitochondria exert biologically relevant effects in the monocrotaline model of PAH [14,15].
In vivo imaging showed that intravenously administered mitochondria predominantly accumulated in the liver and kidneys, with comparatively low signals in the lungs and heart. This distribution suggests that at least part of the benefit to the pulmonary vasculature observed here may be mediated indirectly, through systemic or immunomodulatory mechanisms, rather than exclusively through direct uptake by pulmonary vascular cells [29]. To corroborate this hypothesis, we analyzed plasma samples collected on day 28. The combined therapy decreased IL-6 and IL-1β plasma levels compared with PAH (Figure 9 and Figure S5D). A previous MCT-induced PAH study [30] showed similar results, using higher dosages of mitochondria transplantation (15,000 μg/rat and 1500 μg/rat). Furthermore, the study demonstrated that a low dose of mitochondria was superior to a high dose in protecting against MCT-induced PAH. Herein, we used 100 μg/animal on days 14 and 21 and observed a beneficial effect. This suggests that mitochondria dosage is an important issue when dealing with the PAH phenotype.
Pulmonary vascular remodeling was consistently attenuated, as indicated by reduced perivascular collagen deposition and decreased α-SMA expression. In parallel, the combined treatment reduced vimentin expression and restored VE-cadherin expression (Figure S5B), suggesting partial attenuation of EndMT, a process increasingly recognized as a contributor to pulmonary vascular remodeling in PAH [31,32,33]. Although these measurements were performed in whole-lung homogenates and therefore do not allow cell-specific conclusions, the results support an association between modulation of mitochondrial homeostasis and pathways related to endothelial plasticity. One of these pathways could be related to calcium homeostasis. Although we did not measure lung tissue calcium deposits, α-SMA lung tissue expression is a marker of endothelial–mesenchymal transition dependent on Ca2+ metabolism and was reduced after mitochondrial transplantation. For instance, reduced calcium overloading has been observed after mitochondrial transplantation therapy to correct the pathology in dystrophin-deficient mdx mice [34]. Aligned to this, normalization of the mitochondrial ultrastructure and sarcoplasmic reticulum/mitochondria interactions in mdx muscles was also observed.
The changes in mitochondrial markers should be interpreted cautiously. Sdha and TFAM are commonly used as indices of mitochondrial content and biogenesis [35], but their reduction after treatment does not necessarily imply impaired mitochondrial function. Instead, these changes may reflect normalization of a maladaptive mitochondrial program present in untreated PAH. Similarly, reductions in OPA1 and Mfn-1 expression likely indicate remodeling of mitochondrial dynamics rather than a simple loss of mitochondrial mass. These findings are more consistent with qualitative reprogramming of mitochondrial homeostasis than with a unidirectional increase in mitochondrial biogenesis.
Analysis of mitochondrial respiratory chain activity revealed relatively modest abnormalities in PAH lungs, with selective improvement of Complex I activity after sildenafil or mitochondrial therapy and increased Complex IV activity after solely mitochondrial transplantation (Figure S5C). The absence of additive effects with combination therapy suggests convergence on partially overlapping metabolic pathways. Given the limitations of assessing respiratory chain function in frozen tissue [36], these findings should be interpreted cautiously, but they are consistent with the concept that mitochondrial dysfunction in PAH is subtle and pathway-specific rather than global [14,15]. Previous studies have demonstrated that approximately 90–95% of maximal respiratory capacity is preserved in frozen samples, indicating that this approach can be applied to isolated mitochondria, permeabilized cells, and tissue homogenates with high sensitivity [36]. This limitation raises important questions regarding how mitochondrial respirometry can be reliably performed in multisite clinical studies and retrospective analyses. Further methodological advances are therefore needed to enable robust assessment of mitochondrial function in frozen tissues obtained after surgical resection, particularly from geographically distant clinical centers.
Despite significant improvements in pulmonary hemodynamics and indices of vascular remodeling, RV hypertrophy persisted across all treatment groups (Figure S5A). This dissociation between afterload reduction and structural RV remodeling is consistent with previous reports and may reflect the relatively short duration of treatment, the direct myocardial toxicity of monocrotaline, or the intrinsic resistance of established RV remodeling to rapid reversal [37]. These findings emphasize the need for longer-term studies specifically designed to address myocardial remodeling.
Sildenafil most likely exerted its predominant effects through vasodilation, as reflected by improvements in RVSP and RV outflow tract diameter, with more limited effects on pulmonary arterial muscularization. Although antiproliferative actions of PDE-5 inhibition have been reported [38,39], these appear to be dose- and context-dependent, and the dosing strategy used here was chosen to balance efficacy and tolerability.
This study has several limitations. The mitochondrial dose and administration schedule were extrapolated from previous studies in other disease models, and optimal dosing, timing, and frequency remain unknown [15,40,41]. No dose-response assessment was performed to determine the safety profile of liver-derived mitochondria. At the tested dose (100 μg/animal), liver-derived mitochondria were poorly tolerated in PAH animals. No direct measurements of oxidative stress, calcium deposits, or mitochondrial membrane potential were performed. Previous work has shown that mitochondria isolated from skeletal muscle can attenuate pulmonary hypertension in hypoxia-induced experimental models [15], whereas in the present study, mitochondria were derived from BM-MSCs and tested in the monocrotaline model. These findings support mitochondrial transplantation as a promising therapeutic strategy in cardiopulmonary disease and indicate that tissue-specific metabolic phenotypes may influence therapeutic efficacy and biological effects. The relatively short observation period limits conclusions regarding long-term outcomes, particularly with respect to RV remodeling. Mitochondrial biodistribution and persistence were only partially characterized. In addition, gene expression analyses performed in whole-lung homogenates preclude interpretation of cell-specific mechanisms. Future studies incorporating cell-specific approaches, lineage tracing, proteomics, and metabolomics will be required to define the precise mechanisms by which mitochondrial transplantation modulates pulmonary vascular disease.

4. Materials and Methods

4.1. Study Approval

The study protocol was approved by the Institutional Animal Care and Use Committee of the Health Sciences Center, Federal University of Rio de Janeiro (CEUA 159/21), on 22 June 2022, and complied with the Principles of Laboratory Animal Care and the US National Academy of Sciences Guide for the Care and Use of Laboratory Animals. The study followed the ARRIVE guidelines [42]. Male Wistar rats were housed under controlled conditions (23 °C, 12-h light–dark cycle) with free access to food and water. Only male animals were used to reduce biological variability in this mechanistic study.

4.2. Experimental Design, Randomization, and Blinding

The primary endpoint was RVSP. Secondary endpoints included echocardiographic indices, right ventricular hypertrophy, vascular remodeling, and metabolic measurements.
Animals were randomly allocated to experimental groups using a computer-generated random sequence prepared by an investigator not involved in data acquisition. The group assignment was concealed in sealed, opaque envelopes. Investigators performing echocardiography, hemodynamic measurements, histologic, immunohistochemical, molecular, and respirometry analyses were blinded to group allocation. Treatment administration was not blinded.
Sample size was based on prior experience with the monocrotaline model and on our group’s previous studies evaluating RVSP in interventional PAH experiments [16,17].

4.3. Mitochondrial Sources and Rationale

Two mitochondrial sources were used for distinct purposes. Liver-derived mitochondria were used exclusively for validation, functional characterization, and biodistribution experiments. The outcomes following transplantation of liver-derived mitochondria in PAH animals were unsatisfactory. Briefly, 2000 µg of liver-derived mitochondria were administered on day 14, and all PAH animals died within a few days. Subsequently, the dose was reduced to 100 µg, based on a previous preclinical study from our group [21]. PAH animals again died within a few days after mitochondrial transplantation. In a third experiment, the dose was maintained at 100 µg, but mitochondria derived from BM-MSCs were used. Under these conditions, PAH animals survived the protocol and exhibited beneficial effects. Accordingly, all in vivo therapeutic experiments were performed using BM-MSC–derived mitochondria at a dose of 100 µg per animal. Given the short-term retention of transplanted mitochondria [43], two intravenous jugular injections of 100 µg were administered 7 days apart to ensure full recovery.

4.3.1. Isolation of Mitochondria from Liver Tissue

Mitochondria were isolated from the liver of a healthy male Wistar rat (8 weeks, ~250 g). The liver was excised, minced, and homogenized in isolation buffer containing mannitol (225 mM), sucrose (75 mM), and EDTA (0.2 mM). The homogenate underwent differential centrifugation at 4 °C (1000× g, then 6200× g twice) to obtain a mitochondrial-enriched fraction [44].

4.3.2. Culture of Bone Marrow Mesenchymal Stromal Cells

BM-MSCs were isolated from femurs and tibias of healthy male Wistar rats (7 weeks, 220 ± 10 g). Cells were cultured in Iscove’s modified Dulbecco’s medium supplemented with 10% fetal bovine serum, 10% horse serum, and 1% penicillin/streptomycin at 37 °C in 5% CO2 [17].

4.3.3. Isolation of Mitochondria from BM-MSCs

BM-MSCs (passages 3–5) were harvested, and mitochondria were isolated using a commercial kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. Briefly, the method uses sequential differential centrifugations to separate organelles and other subcellular particles based on their sedimentation rate. To obtain mitochondrial preparations with reduced interference from other cytosolic components, centrifugation for mitochondrial recovery was performed at 3000× g for 15 min at 4 °C. Mitochondrial preparations were made with 1 × 106 BM-MSCs, with a typical yield of 600–800 μg of protein. For flow cytometry characterization, MSCs were pre-stained with 200 nM of Mitotracker Deep Red FM in 10 mL serum-free MEM in the dark for 45 min. Cells were washed with PBS, and the mitochondria were isolated. The final mitochondrial pellet was washed twice and resuspended in PBS. Gating of MSC mitochondria was performed based on FSC/SSC parameters. Analysis was conducted on a FACS CantoII flow cytometer using FACSDiva software, version 6.1.3, and data were analyzed with FlowJo software, version 10 (FlowJo, Ashland, OR, USA). Protein concentration was determined by BCA assay. Mitochondria were administered intravenously within 2 h of isolation to preserve viability [43].

4.3.4. Mitochondrial Oxygen Consumption

Oxygen consumption was measured using an OROBOROS O2k respirometer (Oroboros Instruments, Innsbruck, Austria) at 37 °C. Mitochondria (200 μg protein) were assessed using a standardized SUIT protocol with sequential addition of pyruvate, malate, ADP, cytochrome c, oligomycin, CCCP, and antimycin A. Data are expressed as oxygen flux (pmol O2·s−1·mL−1) [44,45].

4.3.5. Mitochondrial Biodistribution

Mitochondria were labeled with MitoTracker Deep Red and injected intravenously. Animals were euthanized at 3 and 24 h. Heart, lungs, liver, and kidneys were imaged ex vivo using an IVIS™ Lumina XRMS (X-Ray Multi-species optical imaging System, Perkin Elmer, Shelton, CT, USA) [46]. Fluorescence was quantified using Living Image software, version 4.5.2.

4.4. Animal Preparation and Experimental Protocol

For liver-derived mitochondria, forty male Wistar rats (196 ± 16 g, 7 weeks) were randomized to receive an intraperitoneal (i.p.) injection of monocrotaline (60 mg/kg, n = 32) or saline (n = 8). On day 14, animals were anesthetized with isoflurane 2.0% and PAH animals were randomized to receive (n = 8 per group): (1) saline (0.9% NaCl); (2) sildenafil (20 mg/kg/day), oral gavage for 14 days; (3) jugular intravenous injections of isolated liver-derived mitochondria (100 μg/animal on days 14 and 21); or (4) combined treatment with sildenafil and mitochondria.
For BM-MSC–derived mitochondria, a similar experimental protocol was done. Forty male Wistar rats (180 ± 22 g, 7 weeks) were randomized to receive an intraperitoneal (i.p.) injection of monocrotaline (60 mg/kg, PAH group, n = 32) or saline (CTRL group, n = 8) [16,17]. On day 14, animals were anesthetized with isoflurane 2.0% and PAH animals were randomized to receive (n = 8 per group): (1) saline (0.9% NaCl) (PAH); (2) sildenafil (20 mg/kg/day), oral gavage for 14 days (PAH—sil) [47]; (3) jugular intravenous injections of isolated mitochondria (100 μg/animal on days 14 and 21) (PAH—imt); or (4) combined treatment with sildenafil and BM-MSC-derived mitochondria (PAH—sil & imt). On day 28, echocardiography and invasive hemodynamics were repeated, followed by tissue collection [17].

4.4.1. Echocardiography

Transthoracic echocardiography was performed on days 1, 14, and 28 using a UGEO HM70A system (Samsung, San Jose, CA, USA). PAT and PET were measured, and the PAT/PET ratio was used as an indirect index of PAH severity [48,49].

4.4.2. Hemodynamic Measurements

On day 28, RVSP was measured under ketamine/midazolam anesthesia via direct RV puncture using a calibrated pressure transducer system. Pressure signals were recorded over multiple respiratory cycles and averaged for analysis. All measurements were validated by an investigator blinded to group allocation.

4.4.3. Right Ventricular Hypertrophy

The Fulton index (RV weight/[LV weight + septum weight]) was calculated and normalized to body weight [50].

4.4.4. Histology and Immunohistochemistry

Lung sections were stained with Masson’s trichrome for collagen quantification. α-SMA immunohistochemistry was performed to assess muscularization [51,52]. Quantification was performed by an investigator blinded to group allocation.

4.4.5. Reverse Transcription Polymerase Chain Reaction

RNA was extracted from lung tissue, reverse transcribed, and analyzed by qPCR. Expression levels of Sdha, vimentin, VE-cadherin, TFAM, Mfn-1, and OPA1 were normalized to the housekeeping gene GAPDH and calculated using the 2−ΔΔCt method [53]. All analyses were performed by an investigator blinded to the group allocation. Primer sequences are presented in Table S1.

4.4.6. High-Resolution Respirometry in Lung Homogenates

Frozen lung samples were homogenized, and mitochondrial-enriched fractions were obtained. Oxygen consumption was measured to assess Complex I–, Complex II–, and Complex IV–dependent respiration, acknowledging limitations related to frozen tissue [36].

4.4.7. Plasma Levels of Inflammatory Markers by ELISA

Plasma was snap-frozen and stored at −80 °C. Protein levels were quantified via the Bradford assay. IL-6 and IL-1β concentrations were measured using commercial ELISA kits according to the manufacturer’s protocols (PeproTech, Cranbury, NJ, USA). All analyses were performed by investigators blinded to the group allocation.

4.5. Statistical Analysis

There was no exclusion of data points. Normality was assessed using the Kolmogorov–Smirnov test. Data are presented as means ± SD. Student’s t-test was used for day-14 comparisons. One-way ANOVA with Tukey’s post hoc test or Kruskal–Wallis with Dunn’s test was used for day-28 comparisons, as appropriate. Analyses were performed using GraphPad Prism version 9.5.1. p < 0.05 was considered significant.

5. Conclusions

BM-MSC–derived mitochondrial transplantation, particularly when combined with sildenafil, attenuates pulmonary vascular remodeling, reduces plasma inflammatory markers, improves mitochondrial homeostasis, and pulmonary hemodynamics in experimental PAH. These findings support further investigation of mitochondrial-based strategies as adjunctive approaches targeting metabolic dysfunction in pulmonary vascular disease.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms27041761/s1.

Author Contributions

Conceptualization, M.E.d.S.F.O.; formal analysis, M.E.d.S.F.O., N.d.N.R. and D.d.A.F.C.; investigation, M.E.d.S.F.O., R.T.S., N.d.N.R., J.D.S., C.M.d.S., M.M.M., M.M.A.d.S., C.R.S.P., J.D.B., I.A.B., R.G.V., S.S.d.S.S. and J.D.Z.; resources, P.R.M.R., F.F.C. and P.L.S.; writing—original draft preparation, M.E.d.S.F.O.; writing—review and editing, M.E.d.S.F.O., P.R.M.R., F.F.C. and P.L.S.; supervision, P.R.M.R., F.F.C. and P.L.S.; project administration, P.R.M.R., F.F.C. and P.L.S.; funding acquisition, P.R.M.R., F.F.C. and P.L.S. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) (E-26/202.766/2018, E-26/010.001488/2019, E-26/200.080/2026), the National Council for Scientific and Technological Development (CNPq), and the Coordination for the Improvement of Higher Education Personnel (CAPES) (88881.371450/2019-01).

Institutional Review Board Statement

The study protocol was approved by the Institutional Animal Care and Use Committee of the Health Sciences Center, Federal University of Rio de Janeiro (CEUA 159/21) on 22 June 2022.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

The authors thank André Benedito da Silva for support with the experiments, Verônica Cristina dos Santos Lima for animal care, and Lorna O’Brien for copyediting. The authors declare that they have not used AI-generated work in this manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BM-MSCBone marrow mesenchymal stromal cell
CTRLControl
EndMTEndothelial-to-mesenchymal transition
ILInterleukin
Mfn-1Mitofusin-1
OPA1Optic atrophy protein 1
PAHPulmonary arterial hypertension
PATPulmonary artery acceleration time
PETPulmonary ejection time
qPCRQuantitative polymerase chain reaction
RVRight ventricular
RVSPRight ventricular systolic pressure
SALSaline
SdhaSuccinate dehydrogenase complex, subunit A
TFAMMitochondrial transcription factor A
α-SMAα-Smooth muscle actin

References

  1. Poch, D.; Mandel, J. Pulmonary hypertension. Ann. Intern. Med. 2021, 174, ITC49–ITC64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Hill, N.S.; Cawley, M.J.; Heggen-Peay, C.L. New therapeutic paradigms and guidelines for the treatment of pulmonary arterial hypertension. J. Manag. Care Pharm. 2016, 22, S3–S14. [Google Scholar] [CrossRef] [Scilit]
  3. Galiè, N.; Olschewski, H.; Oudiz, R.J.; Torres, F.; Frost, A.; Ghofrani, H.A.; Badesch, D.B.; McGoon, M.D.; McLaughlin, V.V.; Roecker, E.B.; et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ARIES-1 and ARIES-2 randomized, double-blind, placebo-controlled trials. Circulation 2008, 117, 3010–3019. [Google Scholar] [CrossRef] [Scilit]
  4. Olschewski, H.; Simonneau, G.; Galiè, N.; Higenbottam, T.; Naeije, R.; Rubin, L.J.; Nikkho, S.; Speich, R.; Hoeper, M.M.; Behr, J.; et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002, 347, 322–329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Galiè, N.; Ghofrani, H.A.; Torbicki, A.; Barst, R.J.; Rubin, L.J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A.; et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353, 2148–2157, Correction in N. Engl. J. Med. 2006, 354, 2400–2401. [Google Scholar] [CrossRef] [Scilit]
  6. Ghofrani, H.A.; Galiè, N.; Grimminger, F.; Grünig, E.; Humbert, M.; Jing, Z.C.; Keogh, A.M.; Langleben, D.; Kilama, M.O.; Fritsch, A.; et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013, 369, 330–340. [Google Scholar] [CrossRef] [Scilit]
  7. Hoeper, M.M.; Badesch, D.B.; Ghofrani, H.A.; Gibbs, J.S.R.; Gomberg-Maitland, M.; McLaughlin, V.V.; Preston, I.R.; Souza, R.; Waxman, A.B.; Grünig, E.; et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2023, 388, 1478–1490. [Google Scholar] [CrossRef] [Scilit]
  8. Paulin, R.; Michelakis, E.D. The metabolic theory of pulmonary arterial hypertension. Circ. Res. 2014, 115, 148–164. [Google Scholar] [CrossRef] [Scilit]
  9. Alencar, A.K.N.; Cruz, F.F.; Rocco, P.R.M.; Silva, P.L. Metabolic theory of pulmonary arterial hypertension: New molecular roles with disease control. Physiol. Mini Rev. 2022, 15, 1–13. [Google Scholar]
  10. Spees, J.L.; Olson, S.D.; Whitney, M.J.; Prockop, D.J. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. USA 2006, 103, 1283–1288. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Nascimento-Dos-Santos, G.; de Souza-Ferreira, E.; Lani, R.; Faria, C.C.; Araujo, V.G.; Teixeira-Pinheiro, L.C.; Vasconcelos, T.; Gonçalo, T.; Santiago, M.F.; Linden, R.; et al. Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 1866, 165686. [Google Scholar] [CrossRef] [Scilit]
  12. Miao, X.; Jiang, P.; Wang, Z.; Kong, W.; Feng, L. Mitochondrial Transplantation: A Novel Therapeutic Approach for Treating Diseases. MedComm 2025, 6, e70253. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. McCully, J.D.; Cowan, D.B.; Emani, S.M.; Del Nido, P.J. Mitochondrial transplantation: From animal models to clinical use in humans. Mitochondrion 2017, 34, 127–134. [Google Scholar] [CrossRef] [Scilit]
  14. Zhou, J.; Zhang, J.; Lu, Y.; Huang, S.; Xiao, R.; Zeng, X.; Zhang, X.; Wu, H.; Liu, Q.; Wang, L. Mitochondrial transplantation attenuates hypoxia-induced pulmonary arterial hypertension. Oncotarget 2016, 7, 38989–39002. [Google Scholar] [CrossRef] [Scilit]
  15. Hsu, C.H.; Roan, J.N.; Fang, S.Y.; Chiu, M.H.; Cheng, T.T.; Huang, C.C.; Lin, M.W.; Lam, C.F. Transplantation of viable mitochondria improves right ventricular performance and pulmonary artery remodeling in rats with pulmonary arterial hypertension. J. Thorac. Cardiovasc. Surg. 2022, 163, e361–e373. [Google Scholar] [CrossRef] [Scilit]
  16. de Mendonça, L.; Felix, N.S.; Blanco, N.G.; Da Silva, J.S.; Ferreira, T.P.; Abreu, S.C.; Cruz, F.F.; Rocha, N.; Silva, P.M.; Martins, V.; et al. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther. 2017, 8, 220. [Google Scholar] [CrossRef] [Scilit]
  17. Braga, C.L.; Santos, R.T.; da Silva, C.M.; de Novaes Rocha, N.; Felix, N.S.; Medeiros, M.; Melo, M.M.; Silva, J.D.; Teixeira, D.E.; Neves, C.C.; et al. Therapeutic effects of hypoxia-preconditioned bone marrow-derived mesenchymal stromal cells and their extracellular vesicles in experimental pulmonary arterial hypertension. Life Sci. 2023, 329, 121988. [Google Scholar] [CrossRef] [Scilit]
  18. Hill, N.S.; Gillespie, M.N.; McMurtry, I.F. Fifty years of monocrotaline-induced pulmonary hypertension: What has it meant to the field? Chest 2017, 152, 1106–1108. [Google Scholar] [CrossRef] [Scilit]
  19. Shin, H.R.; Lee, G.; Kim, K.H. Mitochondrial Transplantation Therapy: A Novel Approach in the Era of Organelle-Centered Regenerative Medicine. Front. Biosci. 2025, 30, 37006. [Google Scholar] [CrossRef] [Scilit]
  20. Folmes, C.D.; Ma, H.; Mitalipov, S.; Terzic, A. Mitochondria in pluripotent stem cells: Stemness regulators and disease targets. Curr. Opin. Genet. Dev. 2016, 38, 1–7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Caldeira, D.A.F.; Silva, J.D.; Melo, M.M.; Veras, R.G.; McAuley, D.F.; Rocco, P.R.M.; Silva, P.L.; Cruz, F.F.; Krasnodembskaya, A. Transplantation of mesenchymal stromal cell-derived mitochondria alleviates endothelial dysfunction in pre-clinical models of acute respiratory distress syndrome. Stem Cells Transl. Med. 2025, 14, Szaf053. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Folmes, C.D.; Nelson, T.J.; Martinez-Fernandez, A.; Arrell, D.K.; Lindor, J.Z.; Dzeja, P.P.; Ikeda, Y.; Perez-Terzic, C.; Terzic, A. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011, 14, 264–271. [Google Scholar] [CrossRef] [Scilit]
  23. Chung, S.; Dzeja, P.P.; Faustino, R.S.; Terzic, A. Developmental restructuring of the creatine kinase system integrates mitochondrial energetics with stem cell cardiogenesis. Ann. N. Y. Acad. Sci. 2008, 1147, 254–263. [Google Scholar] [CrossRef] [Scilit]
  24. Zhang, J.; Khvorostov, I.; Hong, J.S.; Oktay, Y.; Vergnes, L.; Nuebel, E.; Wahjudi, P.N.; Setoguchi, K.; Wang, G.; Do, A.; et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J. 2011, 30, 4860–4873, Erratum in EMBO J. 2016, 35, 899. [Google Scholar] [CrossRef] [Scilit]
  25. Chang, J.C.; Chang, H.S.; Wu, Y.C.; Cheng, W.L.; Lin, T.T.; Chang, H.J.; Kuo, S.J.; Chen, S.T.; Liu, C.S. Mitochondrial transplantation regulates antitumour activity, chemoresistance, and mitochondrial dynamics in breast cancer. J. Exp. Clin. Cancer Res. 2019, 38, 4860–4873. [Google Scholar] [CrossRef] [Scilit]
  26. Wang, Q.; Wang, X.; Shang, Z.; Zhao, L. Mechanism and prospects of mitochondrial transplantation for spinal cord injury treatment. Stem Cell Res. Ther. 2024, 15, 457. [Google Scholar] [CrossRef] [Scilit]
  27. Shi, X.; Zhang, H.; Fu, B.; Fu, A. Mitotherapy for fatty liver by intravenous administration of exogenous mitochondria in male mice. Front. Pharmacol. 2017, 8, 241. [Google Scholar] [CrossRef] [Scilit]
  28. Clark, M.A.; Shay, J.W. Mitochondrial transformation of mammalian cells. Nature 1982, 295, 605–607. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Cowan, D.B.; Yao, R.; Thedsanamoorthy, J.K.; Snay, E.R.; Thedsanamoorthy, J.K.; Zurakowski, D.; Ericsson, M.; Friehs, I.; Wu, Y.; Levitsky, S.; et al. Intracoronary delivery of mitochondria to the ischemic heart for cardioprotection. PLoS ONE 2016, 11, e0160889. [Google Scholar] [CrossRef] [Scilit]
  30. Huang, T.H.; Chung, S.Y.; Chua, S.; Chai, H.T.; Sheu, J.J.; Chen, Y.L.; Chen, C.H.; Chang, H.W.; Tong, M.S.; Sung, P.H.; et al. Effect of early administration of lower dose versus high dose of fresh mitochondria on reducing monocrotaline-induced pulmonary artery hypertension in rat. Am. J. Transl. Res. 2016, 8, 5151–5168. [Google Scholar] [PubMed]
  31. Lee, S.E.; Yu, S.H.; Kim, I.H.; Kang, Y.C.; Kim, Y.; Yeo, J.S.; Lim, J.H.; Kwon, I.; Kim, J.H.; Park, S.W. Mitochondrial Transplantation Ameliorates Pulmonary Fibrosis by Suppressing Myofibroblast Activation. Int. J. Mol. Sci. 2024, 25, 12783. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Wang, Y.; Wang, G.; Hong, X.; Zhao, J.; Wu, D.; Chen, L.; Liu, X.; Kong, D.; Huang, Q.; Xing, J.; et al. Downregulated mitochondrial transcription factor A enhances mycoplasma infection to promote the metastasis of hepatocellular carcinoma. Cancer Sci. 2023, 114, 1464–1478. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Lebas, M.; Chinigo, G.; Courmont, E.; Bettaieb, L.; Machmouchi, A.; Goveia, J.; Beatovic, A.; Kerckhove, J.V.; Robil, C.; Angulo, F.S.; et al. Integrated single-cell RNA sequencing analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition. Sci. Adv. 2024, 10, eadf6182. [Google Scholar] [CrossRef] [Scilit]
  34. Dubinin, M.V.; Mikheeva, I.B.; Stepanova, A.E.; Igoshkina, A.D.; Cherepanova, A.A.; Semenova, A.A.; Sharapov, V.A.; Kireev, I.I.; Belosludtsev, K.N. Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model. Biomolecules 2024, 14, 316. [Google Scholar] [CrossRef] [Scilit]
  35. Kang, I.; Chu, C.T.; Kaufman, B.A. The mitochondrial transcription factor TFAM in neurodegeneration: Emerging evidence and mechanisms. FEBS Lett. 2018, 592, 793–811. [Google Scholar] [CrossRef] [Scilit]
  36. Acín-Pérez, R.; Benador, I.Y.; Petcherski, A.; Veliova, M.; Benavides, G.A.; Lagarrigue, S.; Caudal, A.; Vergnes, L.; Murphy, A.N.; Karamanlidis, G.; et al. A novel approach to measure mitochondrial respiration in frozen biological samples. EMBO J. 2020, 39, e104073. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Felix, N.S.; de Mendonça, L.; Braga, C.L.; da Silva, J.S.; Samary, C.D.S.; Vieira, J.B.; Cruz, F.; Rocha, N.N.; Zapata-Sudo, G.; Rocco, P.R.M.; et al. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br. J. Pharmacol. 2019, 176, 4462–4473. [Google Scholar] [CrossRef] [Scilit]
  38. Barnett, C.F.; Machado, R.F. Sildenafil in the treatment of pulmonary hypertension. Vasc. Health Risk Manag. 2006, 2, 411–422. [Google Scholar] [CrossRef] [Scilit]
  39. Kang, L.; Liu, X.; Li, Z.; Han, H.; Liu, M.; Zhao, C.; Li, X. Sildenafil Improves Pulmonary Vascular Remodeling in a Rat Model of Persistent Pulmonary Hypertension of the Newborn. J. Cardiovasc. Pharmacol. 2023, 81, 232–239. [Google Scholar] [CrossRef] [Scilit]
  40. Wu, S.F.; Lin, C.Y.; Tsai, R.K.; Wen, Y.T.; Lin, F.H.; Chang, C.Y.; Shen, C.I.; Lin, S.Z.; Harn, H.J.; Chiou, T.W.; et al. Mitochondrial Transplantation Moderately Ameliorates Retinal Degeneration in Royal College of Surgeons Rats. Biomedicines 2022, 10, 2883. [Google Scholar] [CrossRef] [Scilit]
  41. Huang, C.C.; Chiu, H.Y.; Lee, P.H.; Fang, S.Y.; Lin, M.W.; Chen, H.F.; Lee, J.S. Mitochondrial transplantation attenuates traumatic neuropathic pain, neuroinflammation, and apoptosis in rats with nerve root ligation. Mol. Pain 2023, 19, 17448069231210423. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Percie du Sert, N.; Hurst, V.; Ahluwalia, A.; Alam, S.; Avey, M.T.; Baker, M.; Browne, W.J.; Clark, A.; Cuthill, I.C.; Dirnagl, U.; et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020, 18, e3000410. [Google Scholar] [CrossRef] [Scilit]
  43. D’Amato, M.; Morra, F.; Meo, I.D.; Tiranti, V. Mitochondrial Transplantation in Mitochondrial Medicine: Current Challenges and Future Perspectives. Int. J. Mol. Sci. 2023, 24, 1969. [Google Scholar] [CrossRef] [Scilit]
  44. Krumschnabel, G.; Fontana-Ayoub, M.; Sumbalova, Z.; Heidler, J.; Gauper, K.; Fasching, M.; Gnaiger, E. Simultaneous high-resolution measurement of mitochondrial respiration and hydrogen peroxide production. Methods Mol. Biol. 2015, 1264, 245–261. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Walsh, M.A.; Musci, R.V.; Jacobs, R.A.; Hamilton, K.L. A practical perspective on how to develop, implement, execute, and reproduce high-resolution respirometry experiments: The physiologist’s guide to an Oroboros O2k. FASEB J. 2023, 37, e23280. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Tang, S.; Guo, Y.; Yang, Y.; Li, Y.; Gao, Y.; Zhang, C.; Xiong, L. High resolution tracking of macrophage cells in deep organs and lymphatics using fluorescent polymer dots. RSC Adv. 2019, 9, 10966–10975. [Google Scholar] [CrossRef] [Scilit]
  47. Yem, C.H.; Tsai, T.H.; Leu, S.; Chen, Y.L.; Chang, L.T.; Chai, H.T.; Chung, S.Y.; Chua, S.; Tsai, C.Y.; Chang, H.W. Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension. Cytotherapy 2013, 15, 209–223. [Google Scholar] [CrossRef] [Scilit]
  48. Thibault, H.B.; Kurtz, B.; Raher, M.J.; Shaik, R.S.; Waxman, A.; Derumeaux, G.; Halpern, E.F.; Bloch, K.D.; Scherrer-Crosbie, M. Noninvasive assessment of murine pulmonary arterial pressure: Validation and application to models of pulmonary hypertension. Circ Cardiovasc. Imaging 2010, 3, 157–163. [Google Scholar] [CrossRef] [Scilit]
  49. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 2015, 16, 233–270, Erratum in Eur. Heart J. Cardiovasc. Imaging 2016, 17, 412. [Google Scholar] [CrossRef] [Scilit]
  50. Siebenthal, C.; Aubert, J.D.; Mitsakis, P.; Yerly, P.; Prior, J.O.; Nicod, L.P. Pulmonary Hypertension and Indicators of Right Ventricular Function. Front. Med. 2016, 3, 23. [Google Scholar] [CrossRef] [Scilit]
  51. Braga, C.L.; Felix, N.S.; Teixeira, D.E.; Vieira, J.B.; Silva Aguiar, R.P.; Bose, R.M.; Antunes, M.A.; Rocha, N.N.; Caruso-Neves, C.; Cruz, F.F.; et al. Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. Eur. J. Pharmacol. 2020, 887, 173438. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Schermuly, R.T.; Dony, E.; Ghofrani, H.A.; Pullamsetti, S.; Savai, R.; Roth, M.; Sydykov, A.; Lai, Y.J.; Weissmann, N.; Seeger, W.; et al. Reversal of experimental pulmonary arterial hypertension by PDGF inhibition. J. Clin. Investig. 2004, 113, 902–910. [Google Scholar] [CrossRef] [Scilit]
  53. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3, 1101–1108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Ijms 27 01761 g001
Figure 1. Biodistribution of mitochondria derived from bone marrow mesenchymal stromal cells (BM-MSCs) after intravenous administration. BM-MSC–derived mitochondria were labeled with MitoTracker Deep Red and administered intravenously via the jugular vein. (A) Representative ex vivo fluorescence images of the heart, liver, kidneys, and lungs obtained 3 h and 24 h after injection. (B) Quantification of the fluorescence signal (radiant efficiency) in each organ. Data are shown as means ± standard deviation (SD); n = 3 per time point. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test.
Figure 1. Biodistribution of mitochondria derived from bone marrow mesenchymal stromal cells (BM-MSCs) after intravenous administration. BM-MSC–derived mitochondria were labeled with MitoTracker Deep Red and administered intravenously via the jugular vein. (A) Representative ex vivo fluorescence images of the heart, liver, kidneys, and lungs obtained 3 h and 24 h after injection. (B) Quantification of the fluorescence signal (radiant efficiency) in each organ. Data are shown as means ± standard deviation (SD); n = 3 per time point. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test.
Ijms 27 01761 g001
Ijms 27 01761 g002
Figure 2. Echocardiographic assessment of right ventricular outflow and pulmonary artery flow on day 28. (A) Representative echocardiographic images showing pulmonary artery flow (yellow contour) and right ventricular (RV) outflow tract diameter (yellow calipers). (B) Pulmonary artery acceleration time to ejection time ratio (PAT/PET). (C) RV outflow tract diameter. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Figure 2. Echocardiographic assessment of right ventricular outflow and pulmonary artery flow on day 28. (A) Representative echocardiographic images showing pulmonary artery flow (yellow contour) and right ventricular (RV) outflow tract diameter (yellow calipers). (B) Pulmonary artery acceleration time to ejection time ratio (PAT/PET). (C) RV outflow tract diameter. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Ijms 27 01761 g002
Ijms 27 01761 g003
Figure 3. Right ventricular systolic pressure (RVSP). (A) Representative right ventricular pressure tracings. (B) Quantification of RVSP measured on day 28. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Figure 3. Right ventricular systolic pressure (RVSP). (A) Representative right ventricular pressure tracings. (B) Quantification of RVSP measured on day 28. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Ijms 27 01761 g003
Ijms 27 01761 g004
Figure 4. Right ventricular hypertrophy assessed by the Fulton index. The Fulton index was calculated as right ventricle weight divided by left ventricle plus septum weight and normalized to body weight. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Figure 4. Right ventricular hypertrophy assessed by the Fulton index. The Fulton index was calculated as right ventricle weight divided by left ventricle plus septum weight and normalized to body weight. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 8 per group. Data are shown as means ± SD. One-way ANOVA with Tukey’s post hoc test.
Ijms 27 01761 g004
Ijms 27 01761 g005
Figure 5. Perivascular collagen deposition in lung tissue. (A) Representative lung sections stained with Masson’s trichrome showing perivascular collagen (blue). (B) Quantification of perivascular collagen deposition (%). Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as means ± SD. One-way ANOVA with Tukey’s post hoc test (p < 0.05).
Figure 5. Perivascular collagen deposition in lung tissue. (A) Representative lung sections stained with Masson’s trichrome showing perivascular collagen (blue). (B) Quantification of perivascular collagen deposition (%). Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as means ± SD. One-way ANOVA with Tukey’s post hoc test (p < 0.05).
Ijms 27 01761 g005
Ijms 27 01761 g006
Figure 6. Pulmonary arterial muscularization assessed by α-smooth muscle actin (α-SMA) immunostaining. (A) Representative images showing α-SMA staining (brown) in the pulmonary artery wall. (B) Quantification of α-SMA expression (%) in the vascular wall. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. Arrows represent intense pulmonary arterial muscularization in PAH and PAH-sil groups. n = 6 per group. Data are expressed as means ± SD. One-way ANOVA with Tukey’s post hoc test (p < 0.05).
Figure 6. Pulmonary arterial muscularization assessed by α-smooth muscle actin (α-SMA) immunostaining. (A) Representative images showing α-SMA staining (brown) in the pulmonary artery wall. (B) Quantification of α-SMA expression (%) in the vascular wall. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. Arrows represent intense pulmonary arterial muscularization in PAH and PAH-sil groups. n = 6 per group. Data are expressed as means ± SD. One-way ANOVA with Tukey’s post hoc test (p < 0.05).
Ijms 27 01761 g006
Ijms 27 01761 g007
Figure 7. Endothelial-to-mesenchymal transition markers in lung tissue. (A) Vimentin (mesenchymal marker) and (B) VE-cadherin (endothelial marker) gene expression were analyzed by reverse transcriptase quantitative polymerase chain reaction (qPCR). Data were normalized to GAPDH and expressed as fold change relative to the CTRL group. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians and interquartile ranges. Kruskal–Wallis followed by Dunn’s test (p < 0.05).
Figure 7. Endothelial-to-mesenchymal transition markers in lung tissue. (A) Vimentin (mesenchymal marker) and (B) VE-cadherin (endothelial marker) gene expression were analyzed by reverse transcriptase quantitative polymerase chain reaction (qPCR). Data were normalized to GAPDH and expressed as fold change relative to the CTRL group. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians and interquartile ranges. Kruskal–Wallis followed by Dunn’s test (p < 0.05).
Ijms 27 01761 g007
Ijms 27 01761 g008
Figure 8. Expression of genes related to mitochondrial homeostasis in lung tissue. Reverse transcriptase quantitative polymerase chain reaction analysis of (A) Succinate dehydrogenase complex, subunit A (Sdha), (B) mitochondrial transcription factor A (TFAM), (C) optic atrophy protein 1 (OPA1), and (D) mitofusin-1 (Mfn-1). Data were normalized to GAPDH and are expressed as fold change relative to the CTRL group. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians and interquartile ranges. Kruskal–Wallis followed by Dunn’s test (p < 0.05).
Figure 8. Expression of genes related to mitochondrial homeostasis in lung tissue. Reverse transcriptase quantitative polymerase chain reaction analysis of (A) Succinate dehydrogenase complex, subunit A (Sdha), (B) mitochondrial transcription factor A (TFAM), (C) optic atrophy protein 1 (OPA1), and (D) mitofusin-1 (Mfn-1). Data were normalized to GAPDH and are expressed as fold change relative to the CTRL group. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians and interquartile ranges. Kruskal–Wallis followed by Dunn’s test (p < 0.05).
Ijms 27 01761 g008
Ijms 27 01761 g009
Figure 9. Plasma levels of inflammatory markers, IL-6 (A) and IL-1β (B). Data were normalized to total protein content using the Bradford assay. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians with interquartile ranges. Statistical analysis was performed using the Kruskal–Wallis test followed by Dunn’s post hoc test (p < 0.05).
Figure 9. Plasma levels of inflammatory markers, IL-6 (A) and IL-1β (B). Data were normalized to total protein content using the Bradford assay. Groups: CTRL, control; PAH, pulmonary arterial hypertension; PAH-sil, PAH treated with sildenafil (20 mg/kg/day); PAH-imt, PAH treated with BM-MSC–derived mitochondrial fraction (100 µg); PAH-sil & imt, combination therapy. n = 6 per group. Data are presented as medians with interquartile ranges. Statistical analysis was performed using the Kruskal–Wallis test followed by Dunn’s post hoc test (p < 0.05).
Ijms 27 01761 g009
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Onofre, M.E.d.S.F.; Santos, R.T.; Rocha, N.d.N.; Caldeira, D.d.A.F.; Silva, J.D.; Silva, C.M.d.; Melo, M.M.; Silva, M.M.A.d.; Pastor, C.R.S.; Batista, J.D.; et al. Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension. Int. J. Mol. Sci. 2026, 27, 1761. https://doi.org/10.3390/ijms27041761

AMA Style

Onofre MEdSF, Santos RT, Rocha NdN, Caldeira DdAF, Silva JD, Silva CMd, Melo MM, Silva MMAd, Pastor CRS, Batista JD, et al. Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2026; 27(4):1761. https://doi.org/10.3390/ijms27041761

Chicago/Turabian Style

Onofre, Maria E. de S. F., Renata T. Santos, Nazareth de N. Rocha, Dayene de A. F. Caldeira, Johnatas D. Silva, Carla M. da Silva, Monique M. Melo, Mayck M. A. da Silva, Clara R. S. Pastor, Julia D. Batista, and et al. 2026. "Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension" International Journal of Molecular Sciences 27, no. 4: 1761. https://doi.org/10.3390/ijms27041761

APA Style

Onofre, M. E. d. S. F., Santos, R. T., Rocha, N. d. N., Caldeira, D. d. A. F., Silva, J. D., Silva, C. M. d., Melo, M. M., Silva, M. M. A. d., Pastor, C. R. S., Batista, J. D., Botelho, I. A., Veras, R. G., Serra, S. S. d. S., Zeidler, J. D., Rocco, P. R. M., Cruz, F. F., & Silva, P. L. (2026). Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 27(4), 1761. https://doi.org/10.3390/ijms27041761

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop